Moreover, magnesium-l-threonate supplements reduce the enzyme β-secretase (BACE1), reducing levels of APP C-terminal fragments and free APP, reducing AD-associated cognitive impairment and synaptic loss (Li et al., 2014). This evidence concerns the gene APP and Alzheimer disease.